Retatrutide 10mg

Hemi Pharma Retatrutide 10mg is the higher-concentration retatrutide vial in the Hemi Pharma range, supplying 10mg of lyophilised triple GLP-1, GIP and glucagon receptor agonist per vial for subcutaneous administration. It is available exclusively through hemipharmauk.uk, the official UK website for Hemi Pharma pharmaceutical products. The 10mg vial is designed for users who have completed the titration phase on Hemi Pharma Retatrutide 5mg and are running weekly maintenance or advanced doses above 5mg, where the 10mg vial provides significantly greater cost and volume efficiency than the 5mg vial. Every vial carries a unique QR code that connects directly to the Hemi Pharma manufacturer database and confirms the batch, compound and concentration before the seal is broken.

Why the 10mg Vial — Concentration Efficiency at Higher Doses

The decision between Hemi Pharma Retatrutide 5mg and Retatrutide 10mg is determined entirely by the weekly dose being used. At doses of 5mg per week or below, the 5mg vial is appropriate and provides one week of supply or more. At doses above 5mg per week the 10mg vial becomes the more practical choice for three reasons.

First, vial efficiency. At 8mg per week, one 10mg vial provides one week and two days of supply. One 5mg vial at the same dose provides approximately four and a half days. Two 5mg vials are required to complete one week at 8mg per week, meaning more vials need to be opened, managed and reconstituted per week. The 10mg vial eliminates this by providing sufficient compound for more than one week in a single vial.

Second, reconstitution simplicity. The 10mg vial reconstituted with 2ml of bacteriostatic water produces a concentration of 5mg per mL or 5000mcg per mL. On a U100 insulin syringe each unit mark equals 50mcg. An 8mg weekly dose requires 160 units, which can be drawn as a single 160-unit draw or split into two 80-unit injections from the same reconstituted vial. The 10mg vial provides this flexibility without requiring the user to manage two open vials simultaneously.

Third, for users running doses of 4mg per week the 10mg vial provides two and a half weeks of supply compared to just over one week from the 5mg vial, reducing the frequency of reconstitution and the number of vials required over a sustained protocol.

The Retatrutide Mechanism — Triple Receptor Agonism Explained

The pharmacological mechanism of Hemi Pharma Retatrutide 10mg is identical to the 5mg vial. Both vials contain the same compound — retatrutide — at the same quality standard confirmed by independent Janoshik Analytical testing. The difference is only vial size and the reconstitution volume required to achieve the target concentration.

Retatrutide activates three receptor systems simultaneously: the GLP-1 receptor, the GIP receptor and the glucagon receptor. The GLP-1 and GIP receptor agonism produces the appetite suppression, gastric emptying reduction and insulin sensitisation that characterise the incretin receptor agonist class. The glucagon receptor agonism adds direct hepatic fat oxidation stimulation and thermogenic energy expenditure elevation through brown adipose tissue activation — mechanisms entirely absent from semaglutide and tirzepatide at the receptor level.

The clinical significance of this triple mechanism was established in the Phase 2 trial published by Jastreboff et al. (2023) in the New England Journal of Medicine. The trial demonstrated average body weight reduction of 24.2 percent over 48 weeks at the 8mg per week dose — the highest weight loss outcome recorded for any pharmacological compound in a Phase 2 trial to date. The full trial is available at nejm.org. This is the clinical evidence base that makes retatrutide the most advanced body composition compound in the Hemi Pharma peptide range.

Batch Test Results

Every batch of Hemi Pharma Retatrutide 10mg is submitted to Janoshik Analytical before UK market entry. The full certificate is published on the Hemi Pharma lab results page and is independently verifiable at janoshik.com using the unique verification key on the document.

Who Should Use Hemi Pharma Retatrutide 10mg

Hemi Pharma Retatrutide 10mg is appropriate for users who meet all three of the following criteria.

They have completed a titration phase on a GLP-1 receptor agonist compound, either Hemi Pharma Semaglutide, Hemi Pharma Tirzepatide or Hemi Pharma Retatrutide 5mg, and have confirmed individual tolerance to incretin receptor agonism at doses of 4mg per week or above. Beginning retatrutide at 8mg per week without prior titration significantly increases the risk of severe gastrointestinal side effects and discontinuation.

They are running or planning to run weekly retatrutide doses above 5mg per week where the 10mg vial provides meaningful efficiency advantages over the 5mg vial.

They have experience with lyophilised peptide reconstitution, subcutaneous injection technique and the management of GLP-1 class side effects from prior experience with semaglutide or tirzepatide. Retatrutide at higher doses produces more pronounced gastrointestinal adaptation requirements than semaglutide at equivalent treatment duration, and prior experience with the class is valuable for managing this.

Users who are new to GLP-1 receptor agonism should begin with Hemi Pharma Semaglutide 5mg and progress through Hemi Pharma Tirzepatide 5mg before progressing to retatrutide.

Reconstitution Guide — Hemi Pharma Retatrutide 10mg

Hemi Pharma Retatrutide 10mg is supplied as a lyophilised powder and must be reconstituted with bacteriostatic water before use. Bacteriostatic water is not included.

Draw 2ml of bacteriostatic water into a syringe. Insert the needle through the rubber stopper of the Hemi Pharma Retatrutide 10mg vial and inject the water slowly down the inside wall. Do not shake. Swirl gently until the powder dissolves completely. At 2ml of bacteriostatic water per 10mg vial the resulting concentration is 5mg per mL or 5000mcg per mL, the same working concentration as a 5mg vial reconstituted with 1ml. This consistency means dose calculations are identical regardless of which vial size is used at the same reconstitution ratio.

The reconstituted solution should be clear and colourless. Do not use if cloudy, discoloured or containing visible particulates. Store the reconstituted vial in the refrigerator immediately and use within 28 days.

Dosing Protocol — Hemi Pharma Retatrutide 10mg

For users transitioning from the 5mg vial after successful titration, the weekly dose at the point of transition determines how the 10mg vial is used. At 4mg per week one 10mg vial provides two and a half weeks of supply. At 8mg per week one 10mg vial provides one week and two days.

Retatrutide is administered once weekly via subcutaneous injection into the abdomen, outer thigh or upper arm. Rotate injection sites between weekly administrations. Administer at the same time each week. If a dose is missed and fewer than five days have passed, administer as soon as possible. If more than five days have passed, skip the missed dose and resume on the regular schedule.

Side Effects and Safety Considerations

The side effect profile of Hemi Pharma Retatrutide 10mg is identical to the 5mg vial. Gastrointestinal effects including nausea, reduced appetite and loose stools are the most commonly reported. At higher doses of 8mg per week and above these effects are more pronounced than at lower doses, reinforcing the importance of prior titration before reaching higher weekly doses.

The mild heart rate increase associated with glucagon receptor agonism is more pronounced at higher doses. Users running 8mg per week should monitor resting heart rate periodically throughout the protocol. A modest increase of 5 to 10 beats per minute is reported in the clinical trial data and is not associated with arrhythmia, but users with pre-existing cardiac conditions should seek medical guidance before using retatrutide at any dose.

No HPTA suppression. No oestrogen aromatisation. No androgenic activity. Post cycle therapy is not required.

Storage — Hemi Pharma Retatrutide 10mg

Store lyophilised Hemi Pharma Retatrutide 10mg in a refrigerator between 2 and 8 degrees Celsius before reconstitution. Do not freeze. Once reconstituted, store in the refrigerator and use within 28 days. Keep away from direct light. Allow the vial to reach room temperature for 10 to 15 minutes before drawing each weekly dose.

What You Will Need Alongside This Product

Bacteriostatic water for reconstitution — not included, sourced separately. U100 insulin syringes for weekly subcutaneous administration — not included, sourced separately. Users new to retatrutide should begin with Hemi Pharma Retatrutide 5mg for the titration phase. Users comparing all available GLP-1 options should review Hemi Pharma Semaglutide 5mg and Hemi Pharma Tirzepatide 5mg in the Hemi Pharma peptide range.

Hemi Pharma Retatrutide 10mg — Frequently Asked Questions

What is the difference between Hemi Pharma Retatrutide 5mg and 10mg?

Both vials contain the same compound — retatrutide — at the same quality standard confirmed by Janoshik Analytical. The difference is vial size only. The 5mg vial suits users in the titration phase or running weekly doses of 5mg or below. The 10mg vial is more cost and volume efficient for users running weekly doses above 5mg, providing more than one week of supply at 8mg per week from a single reconstituted vial.

Who should use Hemi Pharma Retatrutide 10mg?

Hemi Pharma Retatrutide 10mg is appropriate for users who have completed a titration phase on a GLP-1 class compound, are running or planning to run weekly doses above 5mg and have prior experience with peptide reconstitution and subcutaneous injection. Users new to GLP-1 receptor agonism should begin with Hemi Pharma Semaglutide 5mg and progress through Tirzepatide before reaching retatrutide.

How long does one Hemi Pharma Retatrutide 10mg vial last?

At 4mg per week one 10mg vial provides two and a half weeks of supply. At 8mg per week one vial provides one week and two days. Reconstituted vials should be stored in the refrigerator and used within 28 days regardless of how much compound remains.

What is the clinical evidence for retatrutide?

The Phase 2 trial published by Jastreboff et al. in the New England Journal of Medicine in 2023 showed average body weight reductions of 17.1 percent at 4mg per week and 24.2 percent at 8mg per week over 48 weeks. These represent the highest weight loss outcomes recorded for any pharmacological compound in a Phase 2 clinical trial to date, exceeding both semaglutide and tirzepatide outcomes at equivalent treatment durations.

Has Hemi Pharma Retatrutide 10mg been independently tested?

Yes. Every Hemi Pharma Retatrutide 10mg batch is submitted to Janoshik Analytical before UK market entry. The full certificate is published on the Hemi Pharma lab results page and is independently verifiable at janoshik.com using the unique verification key on the document.

Does Hemi Pharma Retatrutide 10mg require post cycle therapy?

No. Retatrutide does not suppress the HPTA, does not aromatise to oestrogen and has no androgenic activity. Post cycle therapy is not required after Hemi Pharma Retatrutide use at any dose.